Tae-You Kim

发表

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

M. Kudo, A. El-Khoueiry, B. Sangro, 2017, The Lancet.

MRX34, a liposomal miR-34 mimic, in patients with advanced solid tumors: Final dose-escalation results from a first-in-human phase I trial of microRNA therapy.

Keunchil Park, A. Brenner, M. Borad, 2016 .

A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair–Deficient/Microsatellite Instability–High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer

Joon-Oh Park, Tae Won Kim, Tae-You Kim, 2020, Cancer research and treatment : official journal of Korean Cancer Association.

Safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of dose-expansion cohorts from the phase 1/2 CheckMate-040 study.

M. Kudo, A. El-Khoueiry, B. Sangro, 2016 .

Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study

Y. Bang, Tae-You Kim, S. Im, 2015, Cancer research and treatment : official journal of Korean Cancer Association.

Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.

S. Hahn, C. Kang, Tae-You Kim, 2008, Lung cancer.

A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer

Tae Won Kim, Tae-You Kim, Hyeong-Seok Lim, 2021, Investigational New Drugs.

Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy

Joon-Oh Park, S. Park, Tae Won Kim, 2013, Investigational New Drugs.

Redefining the Positive Circumferential Resection Margin by Incorporating Preoperative Chemoradiotherapy Treatment Response in Locally Advanced Rectal Cancer: A Multicenter Validation Study

Tae Hyun Kim, J. Oh, Seung-Yong Jeong, 2017, Cancer research and treatment : official journal of Korean Cancer Association.

A Phase II Study of Bevacizumab, Oxaliplatin, and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer: A Prospective, Multicenter Trial of the Korean Cancer Study Group

Sung Sook Lee, Tae Won Kim, Tae-You Kim, 2014, American journal of clinical oncology.

Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer

S. Park, Tae-You Kim, K. Nishio, 2014, Gastric Cancer.

IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).

M. Kudo, P. Galle, M. Ducreux, 2021, Journal of Clinical Oncology.

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

Yulei N. Wang, M. Kudo, P. Galle, 2020, The New England journal of medicine.

Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.

M. Kudo, P. Galle, M. Ducreux, 2021, The Lancet. Oncology.

A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma

Tae-You Kim, Y. Chao, C. Yen, 2018, Liver Cancer.

Adjuvant chemotherapy with oxaliplatin/5-fluorouracil/leucovorin (FOLFOX) versus 5-fluorouracil/leucovorin (FL) for rectal cancer patients whose postoperative yp stage 2 or 3 after preoperative chemoradiotherapy: Updated results of 3-year disease-free survival from a randomized phase II study (The A

Joon-Oh Park, Tae Won Kim, Tae-You Kim, 2014 .

AZD6244 (ARRY-142886) versus capecitabine (CAP) in patients (pts) with metastatic colorectal cancer (mCRC) who have failed prior chemotherapy

Tae-You Kim, I. Láng, J. Douillard, 2008 .

Phase 1 study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC): Correlation of tumor and serum biomarker data with disease control.

M. Thomas, A. Santoro, Tae-You Kim, 2014 .

Phase I study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC).

J. Berlin, M. Thomas, A. Santoro, 2013 .

Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial.

Joon-Oh Park, S. Yun, Jong Hoon Kim, 2019, Journal of Clinical Oncology.

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

Naotoshi Sugimoto, Yasuhiro Shimada, David Ferry, 2014, The Lancet. Oncology.

Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas

Myung Ah Lee, M. Ahn, Tae-You Kim, 2007, Cancer Chemotherapy and Pharmacology.

Phase I dose-finding study of OPB-111077, a novel STAT3 inhibitor, in patients with advanced hepatocellular carcinoma.

Myung Ah Lee, Tae-You Kim, H. Lim, 2018 .

Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.

M. Rebelatto, M. Borad, G. Abou-Alfa, 2017 .

Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial.

J. Park, H. Choi, J. Oh, 2014, The Lancet. Oncology.

Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology

M. Kudo, P. Galle, J. Llovet, 2021, Liver international : official journal of the International Association for the Study of the Liver.

BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy

Sung-Bae Kim, S. Paik, J. Chiu, 2019, Cancer research and treatment : official journal of Korean Cancer Association.

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

K. Kelnar, Keunchil Park, A. Brenner, 2020, British Journal of Cancer.

Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.

M. Kudo, A. Santoro, A. El-Khoueiry, 2019, Journal of Clinical Oncology.

Nivolumab in Advanced Hepatocellular Carcinoma: Sorafenib-Experienced Asian Cohort Analysis.

M. Kudo, T. Yau, Chiun Hsu, 2019, Journal of hepatology.

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

M. Kudo, A. Santoro, A. El-Khoueiry, 2020, JAMA oncology.

Molecular analysis of the randomized phase II/III study of the anti-IGF-1R antibody dalotuzumab (MK-0646) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory KRAS wild-type metastatic colorectal cancer (mCRC)

J. Lunceford, M. Ayers, E. Schmidt, 2012 .

Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial

Matthew S. Johnson, C. Sofocleous, Tae-You Kim, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiation Response Prediction Model Based on Integrated Clinical and Genomic Data Analysis

Tae-You Kim, S. Im, E. Chie, 2021, Cancer research and treatment.

Targeted next-generation DNA sequencing identifies Notch signaling pathway mutation as a predictor of radiation response

Tae-You Kim, S. Im, E. Chie, 2019, International journal of radiation biology.

Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer

Tae-You Kim, J. W. Kim, Keun-Wook Lee, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients

Myung Ah Lee, M. Kudo, J. Furuse, 2018, Investigational New Drugs.

Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.

M. Kudo, P. Galle, M. Ducreux, 2021, Journal of hepatology.

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

A. Gasbarrini, M. Kudo, J. Bruix, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

Tae-You Kim, I. Láng, J. Douillard, 2011, Investigational New Drugs.

Nivolumab + ipilimumab combination therapy in patients with advanced hepatocellular carcinoma: subgroup analyses from CheckMate 040

M. Kudo, A. Santoro, B. Sangro, 2020, Journal of Hepatology.

Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040.

M. Kudo, A. Santoro, A. El-Khoueiry, 2020 .

Metaplastic Breast Carcinoma: Clinicopathologic Features and Prognostic Value of Triple Negativity

Tae-You Kim, S. Im, I. Park, 2009 .

Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.

Joon-Oh Park, S. Yun, Jong Hoon Kim, 2014, The Lancet. Oncology.

Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy

Yeon-Hee Park, Tae-You Kim, Yoon-Koo Kang, 2007, Cancer Chemotherapy and Pharmacology.

Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor.

Myung Ah Lee, Sung-Bae Kim, Yeon-Hee Park, 2005, Oncology reports.

Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma

Myung Ah Lee, Tae-You Kim, H. Lim, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

Gadoxetic acid-enhanced MRI and diffusion-weighted imaging for the detection of colorectal liver metastases after neoadjuvant chemotherapy

B. Choi, J. Han, J. Lee, 2015, European Radiology.

Erratum: Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab (Investigational New Drugs (2014) 32 (535-541) DOI: 10.1007/s10637-014-0065-x)

Joon-Oh Park, Y. Cho, S. Yun, 2014 .

Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): 10-year follow-up of an open-label, non-inferiority, randomised controlled trial.

J. Park, H. Choi, J. Oh, 2021, The lancet. Gastroenterology & hepatology.

A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First‐line Therapy (KCSG ST10‐01)

Tae-You Kim, S. Oh, J. W. Kim, 2018, The oncologist.

Resminostat and sorafenib combination therapy for advanced hepatocellular carcinoma in patients previously untreated with systemic chemotherapy.

Myung Ah Lee, M. Kudo, J. Furuse, 2017 .

Gefitinib for refractory advanced non-small-cell lung cancer

Tae-You Kim, H. Moriguchi, C. Sato, 2006, The Lancet.

Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression

K. Rau, Tae-You Kim, Joong-Won Park, 2021, British Journal of Cancer.

Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040.

M. Kudo, A. Santoro, A. El-Khoueiry, 2021 .

Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.

M. Kudo, A. El-Khoueiry, B. Sangro, 2017 .

Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.

J. Bruix, R. Finn, T. Yau, 2013, Journal of hepatology.

Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC).

M. Kudo, P. Galle, M. Ducreux, 2020 .

Impact of Lymph Node Ratio on Oncologic Outcomes in ypStage III Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy followed by Total Mesorectal Excision, and Postoperative Adjuvant Chemotherapy

Seung-Yong Jeong, Tae-You Kim, Keun-Wook Lee, 2015, PloS one.

Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment

Tae-You Kim, Y. Kim, Jeong‐Hoon Lee, 2020, Clinical and molecular hepatology.

RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma: Quality-of-life (QoL) results.

Tae-You Kim, N. Sugimoto, G. Bodoky, 2014 .

A Prospective, Multicenter, Phase 2 Study of Imatinib Mesylate in Korean Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor

Joon-Oh Park, D. Shin, Y. Bang, 2009, Oncology.

Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab

P. Galle, M. Ducreux, A. Zhu, 2022, Liver Cancer.

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumors.

J. Berlin, H. Lenz, V. Giranda, 2014 .